Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

High‐sensitive clinical diagnostic method for PTPRZ1‐MET and the characteristic protein structure contributing to ligand‐independent MET activation

28 Feb 2021

Abstract excerpt

BACKGROUND: PTPRZ1-MET (ZM) is a critical genetic alteration driving the progression of lower-grade glioma. Glioma patients harboring ZM could benefit from MET inhibitors. According to the remarkable role of ZM as a driver of glioma progression and indicator of MET inhibitor sensitivity, it is necessary to detect this alteration even when it presents in glioma with relatively fewer copies. METHODS: Herein, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to FOXO transcription factor regulation
Share to Glioma Diagnosis and Treatment
Share to Liver physiology and pathology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33645009
DOI: 10.1111/cns.13627

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High‐sensitive clinical diagnostic method for PTPRZ1‐MET and the characteristic protein structure contributing to ligand‐independent MET activationPMID 33645009Read ↗

Enhanced expression and phosphorylation of the MET oncoprotein by glioma‐specific PTPRZ1–MET fusionsSemantic proximity Read ↗

Extensive MET alterations confer clinical response to MET inhibitors in gliomasSemantic proximity Read ↗

Pan-Cancer Analysis of Oncogenic MET Fusions Reveals Distinct Pathogenomic Subsets with Differential Sensitivity to MET-Targeted TherapySemantic proximity Read ↗

Repurposing passenger amplifications as Trojan horses identifies MPZL1 as a potent target for solid cancersSemantic proximity Read ↗

Molecular characterization of MET fusions from a large real-world Chinese population: A multicenter study.Semantic proximity Read ↗

MET fusions are targetable genomic variants in the treatment of advanced malignancies.Semantic proximity Read ↗

Tumour exosomes from cells harbouring PTPRZ1-MET fusion contribute to a malignant phenotype and temozolomide chemoresistance in glioblastoma.Semantic proximity Read ↗

China special issue on gastrointestinal tumors-NTRK fusion in a large real-world population and clinical utility of circulating tumor DNA genotyping to guide TRK inhibitor treatment.Semantic proximity Read ↗

Met-HER3 crosstalk supports proliferation via MPZL3 in <i>MET</i> -amplified cancer cellsSemantic proximity Read ↗

The MET Oncogene Network of Interacting Cell Surface ProteinsSemantic proximity Read ↗

Identification of a novel MET mutation in high-grade glioma resulting in an auto-active intracellular proteinSemantic proximity Read ↗

Recurrent PTPRZ1-MET fusion and a high occurrence rate of MET exon 14 skipping in brain metastases.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.